FLT3 TriTACs (Harpoon Therapeutics)

N/A

Report date: 2026/03/19 16:58:11

Base Information

Drug NameFLT3 TriTACs (Harpoon Therapeutics)

Drug Alias NameAnti-CD3/anti-FLT3/anti-albumin trispecific T-cell engager (Harpoon Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody +[4]

Mechanisms of ActionSerum albumin modulatorsTyrosine-protein kinase receptor FLT3 modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3Serum albumin

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesHarpoon Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHarpoon Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A